BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23668489)

  • 1. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
    Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
    Khasraw M; Ameratunga M; Grommes C
    Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of antiangiogenic treatment in glioblastoma.
    Chinot OL; Reardon DA
    Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
    Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
    Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-angiogenic therapy for malignant glioma].
    Nagane M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bevacizumab in recurrent glioblastoma.
    Ghiaseddin A; Peters KB
    CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
    Clarke JL
    Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.